Tags

Type your tag names separated by a space and hit enter

Impact of kinins in the treatment of cardiovascular diseases.
Pharmacol Ther. 2012 Jul; 135(1):94-111.P&T

Abstract

In recent years, ACE Inhibitors (ACEIs) and Angiotensin II receptor antagonists (also known as AT1 receptor antagonists (AT1-RAs), angiotensin receptor blockers (ARBs), or Sartans), have become the drugs of choice for the treatment of hypertension, heart and renal failure, coronary artery diseases, myocardial infarction and diabetes. By suppressing angiotensin and potentiating bradykinin effects, ACEIs and ARBs activate hemodynamic, metabolic and cellular mechanisms that not only reduce high blood pressure, but also protect the endothelium, the heart, the kidney and the brain, namely the target organs which are at risk in cardiovascular diseases. Major therapeutic benefits of these drugs are the reduction of cardiovascular events and the amelioration of the quality of life and of the patient survival. Results from large clinical trials have established that ACEIs and ARBs are efficient and safe drugs, suitable for the chronic treatments of cardiovascular diseases. Side effects are rare and easily manageable in most cases. The following is a brief review of the basic actions and mechanisms by which two opposing systems, the renin-angiotensin (RAS) and the kallikrein-kinin (KKS), interact in the regulation of cardiovascular and fluid homeostasis to keep the balance in healthy life and correct the imbalance in pathological conditions. Here we discuss how and why imbalances created by overactive RAS are best corrected by treatments with ACEI or AT1-RAs.

Authors+Show Affiliations

Department of Experimental and Clinical Medicine, University of Ferrara, Ferrara, Italy. rgd@unife.itNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

22537664

Citation

Regoli, Domenico, et al. "Impact of Kinins in the Treatment of Cardiovascular Diseases." Pharmacology & Therapeutics, vol. 135, no. 1, 2012, pp. 94-111.
Regoli D, Plante GE, Gobeil F. Impact of kinins in the treatment of cardiovascular diseases. Pharmacol Ther. 2012;135(1):94-111.
Regoli, D., Plante, G. E., & Gobeil, F. (2012). Impact of kinins in the treatment of cardiovascular diseases. Pharmacology & Therapeutics, 135(1), 94-111. https://doi.org/10.1016/j.pharmthera.2012.04.002
Regoli D, Plante GE, Gobeil F. Impact of Kinins in the Treatment of Cardiovascular Diseases. Pharmacol Ther. 2012;135(1):94-111. PubMed PMID: 22537664.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of kinins in the treatment of cardiovascular diseases. AU - Regoli,Domenico, AU - Plante,Gerard E, AU - Gobeil,Fernand,Jr Y1 - 2012/04/17/ PY - 2012/03/02/received PY - 2012/03/02/accepted PY - 2012/4/28/entrez PY - 2012/4/28/pubmed PY - 2012/9/18/medline SP - 94 EP - 111 JF - Pharmacology & therapeutics JO - Pharmacol. Ther. VL - 135 IS - 1 N2 - In recent years, ACE Inhibitors (ACEIs) and Angiotensin II receptor antagonists (also known as AT1 receptor antagonists (AT1-RAs), angiotensin receptor blockers (ARBs), or Sartans), have become the drugs of choice for the treatment of hypertension, heart and renal failure, coronary artery diseases, myocardial infarction and diabetes. By suppressing angiotensin and potentiating bradykinin effects, ACEIs and ARBs activate hemodynamic, metabolic and cellular mechanisms that not only reduce high blood pressure, but also protect the endothelium, the heart, the kidney and the brain, namely the target organs which are at risk in cardiovascular diseases. Major therapeutic benefits of these drugs are the reduction of cardiovascular events and the amelioration of the quality of life and of the patient survival. Results from large clinical trials have established that ACEIs and ARBs are efficient and safe drugs, suitable for the chronic treatments of cardiovascular diseases. Side effects are rare and easily manageable in most cases. The following is a brief review of the basic actions and mechanisms by which two opposing systems, the renin-angiotensin (RAS) and the kallikrein-kinin (KKS), interact in the regulation of cardiovascular and fluid homeostasis to keep the balance in healthy life and correct the imbalance in pathological conditions. Here we discuss how and why imbalances created by overactive RAS are best corrected by treatments with ACEI or AT1-RAs. SN - 1879-016X UR - https://www.unboundmedicine.com/medline/citation/22537664/Impact_of_kinins_in_the_treatment_of_cardiovascular_diseases_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0163-7258(12)00079-4 DB - PRIME DP - Unbound Medicine ER -